Videos

Centering discussion on two clinical cases of patients with relapsed/refractory multiple myeloma, expert panelists highlight the use of BCMA-targeted teclistamab in this setting.

Future research must address ways to improve the prediction of kidney cancer recurrence to better inform patients, says an expert from the Royal Free London NHS Foundation Trust.

Shared insight on the potential role for immunotherapeutic agents in the setting of microsatellite stable metastatic colorectal cancer.

Centering discussion on KRASG12C-mutated metastatic colorectal cancer, panelists highlight recent clinical studies of targeted agents in this subset of disease.

Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.

Kendra Sweet, MD, discussed several ongoing studies in chronic myeloid leukemia, with some initial results presented at the 2022 American Society of Hematology Annual Meeting and Exposition.

An expert from the University of Texas Southwestern Medical Center questions how providers are currently utilizing stereotactic radiation in the treatment of metastatic kidney cancer.

Patients with kidney cancer should be made aware of trials that have not read out positively in the adjuvant setting, according to an expert from the Royal Free London NHS Foundation Trust.

Kendra Sweet, MD, examined how the data surrounding asciminib in chronic myeloid leukemia will affect the standard of care treatment options.

Kendra Sweet, MD, discussed results of the the phase 2 OPTIC trial, which investigated ponatinib in a group of patients with resistant, chronic phase chronic myeloid leukemia.

Shared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.

Switching to a patient case of brain metastases in HER2+ breast cancer, panelists highlight available therapeutic strategies in this setting.

Following the 2022 ASH Annual Meeting and Exposition, Peter Voorhees, MD; Amrita Krishnan, MD; and Josh Richter, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in blood cancer, as well as what research needs more follow-up.

The panel reviews the treatment approaches for HER2+ mBC with active brain metastases and the factors to consider during treatment decision-making.

Centering discussion on a recent study, experts Thomas Leblanc, MD, and Bhumika Patel, MD, reflect on long-term data with tagraxofusp in BPDCN.

Expert hematologist-oncologists share their perspective on the broad diagnosis and management of blastic plasmacytoid dendritic cell neoplasm (BPDCN).

Virginia Kaklamani, MD, presents the case of a 60-year-old patient with stage III HER2+ mBC with brain metastases.

Ongoing clinical trials are exploring the cytoreductive properties and immunogenic potential of stereotactic radiation in the treatment of patients with metastatic kidney cancer, according to an expert from the University of Texas Southwestern Medical Center.

John Strickler, MD, details the design and outcomes of the MOUNTAINEER trial investigating the combination treatment of tucatinib with trastuzumab for HER2+ metastatic colorectal cancer.

A panel of expert oncologists discusses advances in the treatment of BRAFV600E metastatic colorectal cancer and also reviews novel targets being investigated in the setting of metastatic colorectal cancer.

Experts offer insights on the appropriate treatment for patients with HER2-positive metastatic colorectal cancer.

Deanna Griffie, MSN, AGNP-BC, shares how common toxicities in patients with HER2+ mCRC being treated with trastuzumab deruxtecan are treated at her clinic.

A video preview for an upcoming program reviewing clinical trial data and updates in the multiple myeloma treatment landscape over the last year.

A video preview for an upcoming expert panelist discussion of recent updates in the multiple myeloma treatment landscape.

Following the 2022 ASH Annual Meeting and Exposition, Nakhle Saba, MD; Lindsey Roeker, MD; Javier Pinilla, MD, PhD; and Catherine C. Coombs, MD, participated in a rapid-fire question-and-answer 2-Minute Drill program, hosted by CancerNetwork®. Topics ranged from most exciting data in chronic lymphocytic leukemia and lymphoma, as well as what research needs more follow-up.

Ravi Vij, MD, MBA, suggested that 4-drug regimens may be a new standard for frontline therapy in newly diagnosed multiple myeloma, as oncologists await trial readouts from ongoing clinical trials.

Ravi Vij, MD, MBA, offered additional information about the use of various regimens aimed to treat patients with high-risk, newly diagnosed multiple myeloma, that were read out at the 2022 ASH Annual Meeting.

Ravi Vij, MD, MBA, discussed updated analyses of the phase 3 SWOG S0777 trial, supporting the use of bortezomib, lenalidomide, and dexamethasone in untreated patients with multiple myeloma who do not plan on receiving immediate autologous stem cell transplant.

Susan O’Brien, MD, provides a brief overview of chronic lymphocytic leukemia (CLL), and Seema Ali Bhat, MD, explains the mechanism of BTK inhibitors.

“Much more research” is needed to advance the adjuvant treatment of patients with kidney cancer, according to an expert from the Royal Free London NHS Foundation Trust.